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Background: Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is widely used in re-
fractory cardiogenic shock and cardiac arrest but is characterized by increased left ventricular (LV) 
afterload and consequent development of pulmonary oedema (ECMO lungs). The ProtekSoloTM (Li-
vaNova, IT) cannula is inserted via the right femoral vein to the left atrium, by a trans-septal puncture 
(under the guidance of transesophageal echocardiography and fluoroscopy). This bypasses the LV by 
draining blood from the left atrium to a paracorporeal pump (eg Rotaflow pump (Maquet, DE)) and 
returning it via a femoral artery cannula, thus providing direct unloading of LV.1-3 We aimed to dem-
onstrate our experience with the paracorporeal LV assist device using the ProtekSolo cannula and 
Rotaflow pump (PSp-LVAD). 
Patients and Methods: 7 adult patients underwent PSp-LVAD placement in UHC Zagreb from January 
to December 2020. We divided the patients in two groups: those who required PSp-LVAD to treat ECMO 
TABLE 1. Baseline characteristics.
N 7 N 7
Mean age (years) 56±9.3 Heart rate (beats/min) 90 (85-125)
Sex (male %) 7 (100 %) Urinary output hourly (ml/h) 100 (15-180)
Mean BMI (kg/m2) 25.5±2.9 Laboratory values
Aetiology of cardiogenic shock Lactate (mmol/L) 2.1 (0.4-4.8)
Worsening of chronic heart failure 4 (57.1%) BUN (mmol/L) 11.5 (1.9-19.7)
Acute coronary syndrome 3 (42.9%) Creatinine (umol/L) 91 (61-133)
Duration of disease AST (IU/L) 193 (19-2132)
Cardiomyopathy (years) 8±5.3 ALT (IU/L) 75 (17-566)
Acute coronary syndrome (days) 5±6 NTproBNP (ng/L) 8118 (41-26245)
SAVE score -3 (-13, 6) Inotropic or vasopressor therapy 
before PSp-LVAD placement
VA-ECMO prior to PSp-LVAD 5 (71.4%) Dobutamine 4 (57.1%)
ECMO lungs 4 (57.1%) Milrinone 3 (42.9%)
Infection prior to VA-ECMO 4 (57.1%) Levosimendan 4 (57.1%)
Mean arterial pressure (mmHg) 76 (60-79) Norepinephrine 5 (71.4%)
BMI: body mass index, SAVE: Survival After Veno-arterial Ecmo, VA-ECMO: veno-arterial extra corporeal membrane oxygenation, 
PSp-LVAD: Protek Solo paracorporeal left ventricular assist device, BUN: blood urea nitrogen, AST: aspartate transaminase, ALT 
alanine transaminase, NTproBNP: N-terminal prohormone of brain natriuretic peptide.
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TABLE 2. Outcomes.
ECMO lungs before PSp-LVAD (N=4) No ECMO lungs before PSp-LVAD (N=3)
30-day mortality 3 (75%) 1 (33%)
Survival to decannulation 1 (25%) 1 (33%)
Mean PSp-LVAD days 11±5 32.5±12
VA-ECMO prior to PSp-LVAD 4 (100%) 1 (33%)
Removal of oxygenator 2 (50%) 3 (100%)
Durable LVAD implantation 0 (0%) 1 (33%)
Complications
Infective 4 (100%) 1 (33%)
Bleeding 2 (50%) 1 (33%)
VA-ECMO: veno-arterial extra corporeal membrane oxygenation, PSp-LVAD: Protek Solo paracorporeal left ventricular assist device, LVAD: left ventricular assist device.
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lungs (n=4) and those who received PSp-LVAD 
implantation prior to developing ECMO lungs 
(n=3). In addition to the description of the treated 
patients, we also assessed 30-day all-cause mor-
tality. 
Results: The baseline characteristics of patients 
are shown in Table 1. All patients were male, 
mean age 56±9.3 years. 57.1% of patients under-
went PSp-LVAD placement due to worsening of 
chronic heart failure and 42.9% due to acute coro-
nary syndrome. Concurrent infection was pre-
sent in 57.1% of patients. 71.4% were first on VA-EC-
MO support, of those 80% developed ECMO lungs. 
Laboratory tests (Figure 1) show improvement in 
kidney and liver function after PSp-LVAD place-
ment. Outcomes are shown in Table 2; patients in 
prophylactic group have lower observed 30-day 
mortality rate (33% vs 75%) and longer VA-ECMO 
support duration due to lower mortality. Besides 2 
patients who are still in active treatment, all oth-
ers died during initial hospitalization due to in-
fective complications, predominantly those that 
had a concurrent infection upon institution of the 
PSp-LVAD. 
Conclusion: Pulmonary edema (ECMO lungs) due 
to increased LV afterload is a major complica-
tion of VA-ECMO. Prophylactic LV unloading by 
PSp-LVAD seems associated with lower 30-days 
mortality. 
Figure 1. Laboratory values before and after Protek Solo paracorporeal left 
ventricular assist device placement. 
BUN: blood urea nitrogen, NTproBNP: N-terminal prohormone of brain natriuretic pepti-
de, AST: aspartate transaminase. 
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